Skip to main content
. 2016 Jul 26;7(36):57651–57670. doi: 10.18632/oncotarget.10859

Figure 5. EGFR inhibition is synthetically lethal with savolitinib in a clone-specific manner.

Figure 5

A., immunoblot analysis of total and activated EGFR (pEGFR) levels in parental H1993 cells and clones treated with 2 μM savolitinib for four hours. B., cell viability heatmap for parental H1993 cells and clones treated with the indicated EGFR inhibitors (137 nM) for five days. Clones were seeded in either 0.1% DMSO or 100 nM savolitinib 24 hours prior to treatment. C., five-day viability assay for parental H1993 cells treated with single-agent savolitinib or the indicated EGFR inhibitors. Clones were treated with each EGFR inhibitor alone or in combination with 100 nM savolitinib. Data shown are the mean ± s.d. cell viabilities determined at 412 nM of each EGFR inhibitor, which is a concentration near the middle of the nine-point dose response curve tested. D., immunoblot analysis of parental H1993 cells and clones treated with 0.1% DMSO or 100 nM savolitinib, afatinib or the combination (100 nM each) for eight hours.